Inactive Instrument

Obalon Therapeutics Inc Stock Nasdaq

Equities

US67424L1008

Sales 2024 * 9.99M Sales 2025 * 11.99M Capitalization 4M
Net income 2024 * -6M Net income 2025 * -5M EV / Sales 2024 * 0.4 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.33 x
P/E ratio 2024 *
-0.38 x
P/E ratio 2025 *
-0.47 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Director of Finance/CFO 63 21-06-14
- -
62 -
Members of the board TitleAgeSince
Director/Board Member 66 21-06-14
Chairman 70 21-06-14
Director/Board Member 70 21-06-14
More insiders
Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Sector
-
More about the company